Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
The host virus coexistence is completely dependent on the ba
2020-07-17

The host-virus coexistence is completely dependent on the balance between a strong immune response inhibiting virus replication and immune evasion and survival of the virus with periodic shedding to enable transmission to new hosts. In the process of ensuring this balance, the virus manipulates 7TM
-
How does APC C recognize its substrates
2020-07-17

How does APC/C recognize its substrates and catalyze their ubiquitylation? How are the outcomes and timing of these activities regulated? These questions have driven a decade of structural studies that begin to explain how APC/C interacts with coactivators, substrates, and E2s, and how these interac
-
br Conformational Activation of APC
2020-07-17

Conformational Activation of APC/C Enables Binding to the Coactivator CDC20 APC/C comes to life by binding a coactivator. This is controlled in part by phosphorylation and APC/C conformational changes that expose the UK-5099 for the C box and IR tail of the coactivator. In interphase when mitoti
-
Cyclosporin H receptor C PHNO has been described as a full a
2020-07-17

[11C]-(+)-PHNO has been described as a full agonist at both D2 and D3 receptors [54,55]. [11C]-(+)-PHNO was initially developed as a PET radiotracer for imaging the high affinity state of the D2 receptor (i.e., highD2) as a means of measuring synaptic dopamine changes in response to pharmacologic ch
-
The identification of a gatekeeper mutation
2020-07-17

The identification of a gatekeeper NPPB also suggests that alternative DDR2 inhibitors may be required to overcome acquired resistance. Additional DDR2 inhibitors that have been isolated include the recently identified alkaloid natural products discoipyrroles A-D and the chemotherapeutic Actinomycin
-
Sterol regulatory element binding proteins SREBPs regulate t
2020-07-16

Sterol regulatory element binding proteins (SREBPs) regulate transcription of genes involved in fatty 8-Bromo-cGMP, sodium salt synthesis [38] (fatty acid synthase, and acetyl-CoA carboxylase) as well as triglyceride synthesis [39]. SREBP-1 protein levels are reduced in 3T3-F442A adipocytes [40] and
-
The most common adverse events in relation to udenafil
2020-07-16

The most common adverse events in relation to udenafil treatment are headache and facial flushing; other possible adverse events are febrile sensation, dyspepsia, and visual disturbances. No severe adverse event related to udenafil has been reported thus far. The adverse event rate recorded in the p
-
improve Besides having a remarkable progestogenic effect an
2020-07-16

Besides having a remarkable progestogenic effect, an additional characteristic of DRSP is its strong antimineralocorticoid effect and antiandrogenic action [11]. DRSP is characterized by an antimineralocorticoid effect that is stronger when compared to progesterone. The decreasing synthesis of proge
-
The N terminal amino acid sequence was made for
2020-07-16

The N-terminal amino Swainsonine mg sequence was made for STH2. This sequence showed high similarity (100%) with to trypsin-like found in the human airway classified as serine proteinase that also belongs to peptidase family SI and related also with chymotrypsin-like enzymes (Yasuoka et al., 1997).
-
The inhibition of mRFP Ub E formation
2020-07-16

The inhibition of mRFP-Ub–E1 formation by ginsenosides Re was not in time-dependent in vitro (Fig. 4B). Fifty micrometres ginsenoside Rg1 decreased E1 activity to 0.24- to 0.36-fold over 30min. This finding suggests that ginsenoside Rg1 may irreversibly inhibit mRFP-Ub–E1 formation or a tight-bindin
-
Approximately of the etamicastat dose was recovered
2020-07-16

Approximately 50% of the etamicastat dose was recovered in urine, 30% in the form of etamicastat and 20% in the form of BIA 5-961. These data agree with those from a study with [14C]-labeled etamicastat in healthy subjects, which showed that approximately 95% of the administered radioactivity had be
-
Recently Schenck et al identified an active site
2020-07-16

Recently, Schenck et al. [25] identified an active site asparagine 222 (N222) residue in the Glycine max TyrAp/PDH (GmPDH1) that is responsible for its prephenate substrate specificity. Mutating the single N222 into an acidic residue (i.e. aspartate, D) in the legume TyrAp/PDH shifted from prephenat
-
The lungs dissected from week
2020-07-16

The lungs dissected from 4–5-week mice were cut into small pieces and then immersed in Dulbecco\'s modified Eagle\'s medium (Invitrogen, Carlsbad, CA) containing collagenase II (2 mg/ml), trypsin (2.5 mg/ml), Dnase I (2 mg/ml), penicillin (100 U/ml), and streptomycin (100 μg/ml) for 12 hours at 37 °
-
From materials science it is known
2020-07-16

From materials science, it is known that the differences in the annealing temperature is the main factor that mostly influences La (Takai et al., 2003, Cançado et al., 2006). In analogy, controlling the pyrolysis temperature and caspase inhibitor during residues burning might be a key aspect to rep
-
Collectively these data suggest the potential clinical
2020-07-16

Collectively, these data suggest the potential clinical utility of COMT inhibitors for the treatment of addiction disorders. Similar to current pharmacotherapies such as naltrexone, tolcapone\'s effects were not ethanol specific, therefore tolcapone may be effective in reducing other drug reinforced
15383 records 758/1026 page Previous Next First page 上5页 756757758759760 下5页 Last page